2 completed, 2 recruiting, 1 active not recruiting. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Encaleret: new trials by email Literature Review of Encaleret trials Research Report on Encaleret
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism Encaleret, Placebo - Hypoparathyroidism, Chronic Hypoparathyroidism | Phase 3 | Recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 160 | 2026-08-31 | 2026-09-16 |
| Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) Encaleret - Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 / Phase 3 | Recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 28 | 2026-01-30 | 2026-04-22 |
| PTH-independent Effects of Encaleret encaleret - Post-Surgical Hypoparathyroidism | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 13 | 2023-09-01 | 2026-03-11 |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
| Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 Encaleret - Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 | Completed | Calcilytix Therapeutics, Inc., a BridgeBio company | 13 | 2020-09-20 | 2024-11-19 |
Hypoparathyroidism (3) · Hypercalciuric Hypocalcemia, Familial (2) · Hypocalcemia (2) · Calcium Metabolism Disorders (1) · Hypercalciuria (1) · Metabolic Diseases (1) · Muscular Diseases (1) · Musculoskeletal Abnormalities (1) · Musculoskeletal Diseases (1) · Nephrocalcinosis (1) · Nephrolithiasis (1)
Calcilytix Therapeutics, Inc., a BridgeBio company (4) · National Institute of Dental and Craniofacial Research (NIDCR) (1)
United States (5) · Canada (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Denmark (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1)